Skip to main content
Home > BioCentury on BioBusiness > Analysts

Chronological Index of BioCentury, The Bernstein Report on BioBusiness: Analyst Picks & Changes

BioCentury, The Bernstein Report on BioBusiness Current Issue
  • Analyst picks & changes

    Analyst picks & changes Company Bank Analyst Coverage Opinion Wk chg 5/14 cls Celldex Therapeutics Inc. (NASDAQ:CLDX) Needham Mark Monane Price target Buy 20% $9.01 Monane raised his target to $12 from…

    Published on 5/17/2010
  • Analyst picks & changes

    Analyst picks & changes Company Bank Analyst Coverage Opinion Wk chg 5/7 cls Elan Corp. plc (NYSE:ELN) UBS Guillaume van Renterghem Upgrade Neutral (from sell) -10% $6.02 van Renterghem upgraded after …

    Published on 5/10/2010
  • Analyst picks & changes

    Analyst picks & changes Company Bank Analyst Coverage Opinion Wk chg 4/30 cls AMAG Pharmaceuticals Inc. Baird Christopher Raymond Price target Market outperform -6% $34.15 (NASDAQ:AMAG) Jefferies Eun …

    Published on 5/3/2010
  • Analyst picks & changes

    Analyst picks & changes Company Bank Analyst Coverage Opinion Wk chg 4/23 cls Affymax Inc. (NASDAQ:AFFY) Summer Street Carol Werther Price target Buy 2% $24.47 Werther lowered her target to $36 from $49…

    Published on 4/26/2010
  • Analyst picks & changes

    Analyst picks & changes Company Bank Analyst Coverage Opinion Wk chg 4/16 cls Acorda Therapeutics Inc. (NASDAQ:ACOR) Leerink Joshua Schimmer Upgrade Market outperform (from market perform) 7% $37.85 …

    Published on 4/19/2010
  • Analyst picks & changes

    Analyst picks & changes Company Bank Analyst Coverage Opinion Wk chg 4/9 cls Actelion Ltd. (SIX:ATLN) UBS Martin Wales Upgrade Buy (from neutral) 3% CHF49.85 Wales said he thinks the shares have been …

    Published on 4/12/2010
  • Analyst picks & changes

    Analyst picks & changes Company Bank Analyst Coverage Opinion Wk chg 4/1 cls Ardea Biosciences Inc. (NASDAQ:RDEA) Brean Murray Jonathan Aschoff Price target Buy 9% $20.50 JMP Securities Liisa Bayko …

    Published on 4/5/2010
  • Analyst picks & changes

    Analyst picks & changes Company Bank Analyst Coverage Opinion Wk chg 3/26 cls Cell Therapeutics Inc. (NASDAQ:CTIC; Milan:CTIC) Rodman Reni Benjamin Downgrade Market perform (from market outperform) -30%…

    Published on 3/29/2010
  • Analyst Picks & Changes

    Analyst picks & changes Company Bank Analyst Coverage Opinion Wk chg 3/19 cls Alkermes Inc. (NASDAQ:ALKS) BMO Capital Markets Robert Hazlett Price target Market perform 6% $12.94 Jefferies David …

    Published on 3/22/2010
  • Analyst picks & changes

    Analyst picks & changes Company Bank Analyst Coverage Opinion Wk chg 3/12 cls Amylin Pharmaceuticals Inc. (NASDAQ:AMLN) Jefferies Thomas Wei Price target Buy 2% $20.26 Wei raised his target to $30 from…

    Published on 3/15/2010
  • Analyst Picks & Changes

    Analyst picks & changes Company Bank Analyst Coverage Opinion Wk chg 3/5 cls Actelion Ltd. (SIX:ATLN) Jefferies Peter Welford Price target Buy -13% CHF47.80 Welford lowered his target to CHF73 from …

    Published on 3/8/2010
  • Analyst picks & changes

    Analyst picks & changes Company Bank Analyst Coverage Opinion Wk chg 2/26 cls Acorda Therapeutics Inc. (NASDAQ:ACOR) Merriman Curhan Ford Michael King Price target Buy -5% $30.18 King raised his target …

    Published on 3/1/2010
  • Analyst Picks & Changes

    Analyst picks & changes Company Bank Analyst Coverage Opinion Wk chg 2/19 cls Ardea Biosciences Inc. (NASDAQ:RDEA) Brean Murray Jonathan Aschoff Price target Buy $14.20 -3% Aschoff raised his target to…

    Published on 2/22/2010
  • Analyst picks & changes

    Analyst picks & changes Company Bank Analyst Coverage Opinion Wk chg 2/12 cls Biogen Idec Inc. (NASDAQ:BIIB) Baird Christopher Raymond Price target Neutral 3% $55.21 Jefferies Eun Yang Price target …

    Published on 2/15/2010
  • Analyst picks & changes

    Analyst picks & changes Company Bank Analyst Coverage Opinion Wk chg 2/5 cls Achillion Pharmaceuticals Inc. (NASDAQ:ACHN) Wedbush Y. Katherine Xu Upgrade Market outperform (from neutral) 1% $2.38 Xu …

    Published on 2/8/2010
  • Analyst picks & changes

    Analyst picks & changes Company Bank Analyst Coverage Opinion Wk chg 1/29 cls Abraxis BioScience Inc. (NASDAQ:ABII) Merriman Curhan Ford Michael King Downgrade Neutral (from buy) -3% $40.85 King …

    Published on 2/1/2010
  • Analysts Picks & Changes

    Analyst picks & changes Company Bank Analyst Coverage Opinion Wk chg 1/22 cls China Nuokang Bio-Pharmaceutical Inc. (NASDAQ:NKBP) Jefferies Marko Kozul New Buy -11% $7.98 Kozul set a $13 target. He …

    Published on 1/25/2010
  • Analyst Picks & Changes

    Analyst picks & changes Company Bank Analyst Coverage Opinion Wk chg 1/15 cls Addex Pharmaceuticals Ltd. (SIX:ADXN) Jefferies Peter Welford Downgrade Underperform (from hold) -4% CHF13.70 Welford also …

    Published on 1/18/2010
  • Analyst Picks & Changes

    Analyst picks & changes Company Bank Analyst Coverage Opinion Wk chg 1/8 cls Affymax Inc. (NASDAQ:AFFY) Baird Christopher Raymond Price target Market outperform -7% $23.00 Raymond raised his target to $…

    Published on 1/11/2010
  • Analyst picks & changes

    Analyst picks & changes Company Bank Analyst Coverage Opinion Wk chg 12/31 cls BioMS Medical Corp. (TSX:MS) Hapoalim Raghuram Selvaraju Upgrade Hold (from sell) -4% C$0.33 Rodman Elemer Piros Upgrade…

    Published on 1/4/2010
  • Analysts Picks & Changes

    Analyst picks & changes Company Bank Analyst Coverage Opinion Wk chg 12/18 cls Addex Pharmaceuticals Ltd. (SIX:ADXN) Jefferies Peter Welford Rating change Hold -60% CHF15.70 Welford moved his rating …

    Published on 12/21/2009
  • Analyst picks & changes

    Analyst picks & changes Company Bank Analyst Coverage Opinion Wk chg 12/11 cls Affymetrix Inc. (NASDAQ:AFFX) UBS Derik de Bruin Price target Neutral 13% $5.55 de Bruin lowered his target to $5.50 from $…

    Published on 12/14/2009
  • Analyst Picks & Changes

    Analyst picks & changes Company Bank Analyst Coverage Opinion Wk chg 12/4 cls Alnylam Pharmaceuticals Inc. (NASDAQ:ALNY) Roth Capital Partners Andrew Vaino Downgrade Hold (from buy) 4% $17.45 Vaino also…

    Published on 12/7/2009
  • Analysts Picks & Changes

    Analyst picks & changes Company Bank Analyst Coverage Opinion Wk chg 11/20 cls Exelixis Inc. (NASDAQ:EXEL) Merriman Curhan Ford Joe Pantginis Downgrade Neutral (from buy) -7% $6.71 Pantginis also …

    Published on 11/23/2009
  • Analyst Picks & Changes

    Analyst picks & changes Company Bank Analyst Coverage Opinion Wk chg 11/13 cls Enzon Pharmaceuticals Inc. (NASDAQ:ENZN) BMO Capital Markets Robert Hazlett Price target Market perform 10% $9.88 Hazlett …

    Published on 11/16/2009

< Previous   1  2  3  4  5  6  7  8  9  Next >
Subscribe Now
Free Trial

About BioCentury

Decision-shaping business intelligence for the global biotech and pharma industry since 1993

Log In


Forgot password  |  Forgot Login


If you are a subscriber, but have forgotten or have never received a password, please go here and ask us to send you a new one.

BioCentury on BioBusiness

BioCentury, The Bernstein Report on BioBusiness is globally recognized for industry analysis, interpretation and commentary on:

  • Corporate Strategy
  • Product Discovery and Development
  • Finance
  • Emerging Companies
  • Regulatory Policy
  • Public Policy